Replies to post #173659 on Biotech Values

[DewDiligence]

My sense though is that it would make a big difference for the ABBV regimen if there was at least one subgroup where it shows (or at least appears to show) a distinct advantage over the GILD offerings.

Treatment-experienced GT1b w/o cirrhosis is such a subgroup, as noted in #msg-96645615.